Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.

Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler JL, Wang J, Zhao R, Kirk J, Chen X, Tang DG.

Nat Commun. 2018 Sep 6;9(1):3600. doi: 10.1038/s41467-018-06067-7.

2.

Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway.

Tu C, Fiandalo MV, Pop E, Stocking JJ, Azabdaftari G, Li J, Wei H, Ma D, Qu J, Mohler JL, Tang L, Wu Y.

J Proteome Res. 2018 Sep 7;17(9):2963-2977. doi: 10.1021/acs.jproteome.8b00135. Epub 2018 Aug 3.

PMID:
30014700
3.

Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.

Cook SF, Fiandalo MV, Watt DS, Wu Y, Mohler JL, Bies RR.

Prostate. 2018 Jun 25. doi: 10.1002/pros.23665. [Epub ahead of print]

PMID:
29938815
4.

Modelling attrition and nonparticipation in a longitudinal study of prostate cancer.

Spiers S, Oral E, Fontham ETH, Peters ES, Mohler JL, Bensen JT, Brennan CS.

BMC Med Res Methodol. 2018 Jun 20;18(1):60. doi: 10.1186/s12874-018-0518-6.

5.

NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.

Carroll PH, Mohler JL.

J Natl Compr Canc Netw. 2018 May;16(5S):620-623. doi: 10.6004/jnccn.2018.0036.

PMID:
29784740
6.

Calcium, magnesium, and whole-milk intakes and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP).

Steck SE, Omofuma OO, Su LJ, Maise AA, Woloszynska-Read A, Johnson CS, Zhang H, Bensen JT, Fontham ETH, Mohler JL, Arab L.

Am J Clin Nutr. 2018 May 1;107(5):799-807. doi: 10.1093/ajcn/nqy037.

PMID:
29722851
7.

Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.

Allott EH, Farnan L, Steck SE, Song L, Arab L, Su LJ, Fontham ETH, Mohler JL, Bensen JT.

Prostate. 2018 Aug;78(11):857-864. doi: 10.1002/pros.23644. Epub 2018 May 1.

PMID:
29717502
8.

A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer.

Mohler JL.

Am J Clin Exp Urol. 2018 Apr 1;6(2):101-106. eCollection 2018. Review.

9.

Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy.

Huben NB, Hussein AA, May PR, Whittum M, Krasowski C, Ahmed YE, Jing Z, Khan H, Kim HL, Schwaab T, Underwood W, Kauffman EC, Mohler JL, Guru KA.

J Endourol. 2018 Aug;32(8):730-736. doi: 10.1089/end.2018.0249.

PMID:
29631438
10.

Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.

Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL.

Oncotarget. 2018 Jan 10;9(13):11227-11242. doi: 10.18632/oncotarget.24107. eCollection 2018 Feb 16.

11.

Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Fiandalo MV, Wilton JH, Mantione KM, Wrzosek C, Attwood KM, Wu Y, Mohler JL.

Prostate. 2018 Feb;78(3):213-221. doi: 10.1002/pros.23459. Epub 2017 Dec 1.

PMID:
29194687
12.

Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.

Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx084.

13.

Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4).

Frasinyuk MS, Zhang W, Wyrebek P, Yu T, Xu X, Sviripa VM, Bondarenko SP, Xie Y, Ngo HX, Morris AJ, Mohler JL, Fiandalo MV, Watt DS, Liu C.

Org Biomol Chem. 2017 Sep 20;15(36):7623-7629. doi: 10.1039/c7ob01584d.

14.

Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.

Nunez Bragayrac LA, Murekeyisoni C, Vacchio MJ, Attwood K, Mehedint DC, Mohler JL, Azabdaftari G, Xu B, Kauffman EC.

Prostate. 2017 Jul;77(10):1076-1081. doi: 10.1002/pros.23364. Epub 2017 May 26.

PMID:
28547760
15.

Lipid degradation promotes prostate cancer cell survival.

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG.

Oncotarget. 2017 Jun 13;8(24):38264-38275. doi: 10.18632/oncotarget.16123.

16.

The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.

Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ETH, Hendrix LH, Farnan L, Olshan AF, Bensen JT.

Prostate. 2017 Jun;77(8):878-887. doi: 10.1002/pros.23342. Epub 2017 Mar 6.

17.

Unit Nonresponse in a Population-Based Study of Prostate Cancer.

Oral E, Simonsen N, Brennan C, Berken J, Su LJ, Mohler JL, Bensen JT, Fontham ET.

PLoS One. 2016 Dec 16;11(12):e0168364. doi: 10.1371/journal.pone.0168364. eCollection 2016.

18.

Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robot-assisted radical cystectomy for bladder cancer.

Hussein AA, Hinata N, Dibaj S, May PR, Kozlowski JD, Abol-Enein H, Abaza R, Eun D, Khan MS, Mohler JL, Agarwal P, Pohar K, Sarle R, Boris R, Mane SS, Hutson A, Guru KA.

BJU Int. 2017 Jun;119(6):879-884. doi: 10.1111/bju.13748. Epub 2017 Jan 18.

19.

Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.

Su S, Parris AB, Grossman G, Mohler JL, Wang Z, Wilson EM.

Prostate. 2017 Apr;77(5):505-516. doi: 10.1002/pros.23288. Epub 2016 Dec 14.

PMID:
27976415
20.

A four gene signature predictive of recurrent prostate cancer.

Komisarof J, McCall M, Newman L, Bshara W, Mohler JL, Morrison C, Land H.

Oncotarget. 2017 Jan 10;8(2):3430-3440. doi: 10.18632/oncotarget.13837.

21.

Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation.

Hussein AA, Ghani KR, Peabody J, Sarle R, Abaza R, Eun D, Hu J, Fumo M, Lane B, Montgomery JS, Hinata N, Rooney D, Comstock B, Chan HK, Mane SS, Mohler JL, Wilding G, Miller D, Guru KA; Michigan Urological Surgery Improvement Collaborative and Applied Technology Laboratory for Advanced Surgery Program.

J Urol. 2017 May;197(5):1237-1244. doi: 10.1016/j.juro.2016.11.100. Epub 2016 Nov 29.

PMID:
27913152
22.

The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.

Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ET, Hendrix LH, Farnan L, Olshan AF, Bensen JT.

Cancer Causes Control. 2016 Dec;27(12):1475-1485. Epub 2016 Nov 9.

23.

Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy.

Ondracek RP, Kattan MW, Murekeyisoni C, Yu C, Kauffman EC, Marshall JR, Mohler JL.

J Natl Compr Canc Netw. 2016 Nov;14(11):1395-1401.

24.

Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort.

Holmes JA, Bensen JT, Mohler JL, Song L, Mishel MH, Chen RC.

Cancer. 2017 Jan 1;123(1):138-143. doi: 10.1002/cncr.30315. Epub 2016 Sep 13.

25.

Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project.

Allott EH, Arab L, Su LJ, Farnan L, Fontham ET, Mohler JL, Bensen JT, Steck SE.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):48-54. doi: 10.1038/pcan.2016.39. Epub 2016 Sep 6.

PMID:
27595916
26.

Characterization of Prostate Cancer in a Functional Eunuch.

Stocking JJ, Fiandalo MV, Pop EA, Wilton JH, Azabdaftari G, Mohler JL.

J Natl Compr Canc Netw. 2016 Sep;14(9):1054-60.

27.

Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis.

Hussein AA, Dibaj S, Hinata N, Field E, O'leary K, Kuvshinoff B, Mohler JL, Wilding G, Guru KA.

Urology. 2016 Nov;97:124-129. doi: 10.1016/j.urology.2016.06.063. Epub 2016 Aug 1.

PMID:
27491964
28.

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S.

Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016. doi: 10.1158/1078-0432.CCR-16-0137. [Epub ahead of print] Retraction in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3973.

PMID:
27458247
29.

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari G, Mohler JL, Liu S, Heemers HV.

Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.

30.

Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?

Mohler JL.

J Natl Compr Canc Netw. 2016 Jun;14(6):701-3. No abstract available.

PMID:
27283162
31.

Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S.

Prostate. 2016 Sep;76(12):1067-77. doi: 10.1002/pros.23190. Epub 2016 Jun 8.

PMID:
27271795
32.

Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP).

Antwi SO, Steck SE, Su LJ, Hebert JR, Zhang H, Craft NE, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L.

Prostate. 2016 Sep;76(12):1053-66. doi: 10.1002/pros.23189. Epub 2016 Jun 8.

33.

Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management.

Mohler JL.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):663-5.

PMID:
27226508
34.

Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.

Al-Tartir T, Murekeyisoni C, Attwood K, Badkhshan S, Mehedint D, Safwat M, Guru K, Mohler JL, Kauffman EC.

J Urol. 2016 Oct;196(4):1061-8. doi: 10.1016/j.juro.2016.05.003. Epub 2016 May 6.

PMID:
27157375
35.

Antineoplastic Isoflavonoids Derived from Intermediate ortho-Quinone Methides Generated from Mannich Bases.

Frasinyuk MS, Mrug GP, Bondarenko SP, Khilya VP, Sviripa VM, Syrotchuk OA, Zhang W, Cai X, Fiandalo MV, Mohler JL, Liu C, Watt DS.

ChemMedChem. 2016 Mar 17;11(6):600-11. doi: 10.1002/cmdc.201600008. Epub 2016 Feb 17.

36.

Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.

Doshi C, Vacchio M, Attwood K, Murekeyisoni C, Mehedint DC, Badkhshan S, Azabdaftari G, Sule N, Guru KA, Mohler JL, Kauffman EC.

Prostate. 2016 Jun;76(8):715-21. doi: 10.1002/pros.23166. Epub 2016 Feb 16.

37.

Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action.

DePriest AD, Fiandalo MV, Schlanger S, Heemers F, Mohler JL, Liu S, Heemers HV.

Database (Oxford). 2016 Feb 13;2016. pii: bav125. doi: 10.1093/database/bav125. Print 2016.

38.

Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study.

Vance TM, Wang Y, Su LJ, Fontham ET, Steck SE, Arab L, Bensen JT, Mohler JL, Chen MH, Chun OK.

Nutr Cancer. 2016;68(2):214-24. doi: 10.1080/01635581.2016.1134596. Epub 2016 Feb 4.

39.

Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina-Louisiana Prostate Cancer Project.

Allott EH, Farnan L, Steck SE, Arab L, Su LJ, Mishel M, Fontham ET, Mohler JL, Bensen JT.

Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):670-7. doi: 10.1158/1055-9965.EPI-15-0631. Epub 2016 Jan 27.

40.

Prostate Cancer, Version 1.2016.

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

PMID:
26733552
41.

Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer.

Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK.

Br J Nutr. 2016 Jan 14;115(1):68-74. doi: 10.1017/S0007114515004249. Epub 2015 Nov 2.

PMID:
26521663
42.

Application of Mannich bases to the synthesis of hydroxymethylated isoflavonoids as potential antineoplastic agents.

Frasinyuk MS, Mrug GP, Bondarenko SP, Sviripa VM, Zhang W, Cai X, Fiandalo MV, Mohler JL, Liu C, Watt DS.

Org Biomol Chem. 2015 Dec 14;13(46):11292-301. doi: 10.1039/c5ob01828e. Epub 2015 Sep 29.

43.

Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants.

Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK.

Prostate Cancer. 2015;2015:728046. doi: 10.1155/2015/728046. Epub 2015 Aug 18.

44.

Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.

Payne Ondracek R, Cheng J, Gangavarapu KJ, Azabdaftari G, Woltz J, Brese E, Omilian A, Bshara W, Huss WJ, Mohler JL, Marshall JR.

Prostate. 2015 Dec;75(16):1910-5. doi: 10.1002/pros.23087. Epub 2015 Sep 9.

45.

Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP).

Antwi SO, Steck SE, Su LJ, H├ębert JR, Zhang H, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L.

Prostate. 2015 Sep;75(13):1419-35. doi: 10.1002/pros.23025. Epub 2015 Jun 5.

46.

Simulation-based training in robot-assisted surgery: current evidence of value and potential trends for the future.

Hanzly MI, Al-Tartir T, Raza SJ, Khan A, Durrani MM, Fiorica T, Ginsberg P, Mohler JL, Kuvshinoff B, Guru KA.

Curr Urol Rep. 2015 Jun;16(6):41. doi: 10.1007/s11934-015-0508-8. Review.

PMID:
26003110
47.

NCCN Roundtable:Value-Based Decision-Making at the Bedside.

Bach PB, Edge SB, House L, Malin J, Mohler JL, Goodman C.

J Natl Compr Canc Netw. 2015 May;13(5 Suppl):659-61.

PMID:
25995423
48.

Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.

Raza SJ, Wilson T, Peabody JO, Wiklund P, Scherr DS, Al-Daghmin A, Dibaj S, Khan MS, Dasgupta P, Mottrie A, Menon M, Yuh B, Richstone L, Saar M, Stoeckle M, Hosseini A, Kaouk J, Mohler JL, Rha KH, Wilding G, Guru KA.

Eur Urol. 2015 Oct;68(4):721-8. doi: 10.1016/j.eururo.2015.04.021. Epub 2015 May 16.

PMID:
25985883
49.

Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.

Steck SE, Arab L, Zhang H, Bensen JT, Fontham ET, Johnson CS, Mohler JL, Smith GJ, Su JL, Trump DL, Woloszynska-Read A.

PLoS One. 2015 Apr 28;10(4):e0125151. doi: 10.1371/journal.pone.0125151. eCollection 2015.

50.

Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.

Cheng J, Ondracek RP, Mehedint DC, Kasza KA, Xu B, Gill S, Azabdaftari G, Yao S, Morrison CD, Mohler JL, Marshall JR.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):182-9. doi: 10.1038/pcan.2015.11. Epub 2015 Apr 14.

Supplemental Content

Loading ...
Support Center